(Q63832891)
Statements
EXALT (English)
0 references
A 1-year, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Zoledronic Acid 5 mg (Aclasta®) on Bone Mineral Density in Patients With Multiple Sclerosis Followed by a 1-year Open-label Treatment Phase (English)
0 references
October 2010
0 references
June 2012
0 references
29
0 references
18 year
0 references
75 year
0 references